Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.67 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12093045 | 1.00 | CHRNB2 (0.67) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL18689619 | 0.98 | CHRNB2 (0.65) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| SCHEMBL7216173 | 0.89 | CHRNB2 (0.68) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| SCHEMBL7809874 | 0.82 | CHRNB2 (0.55) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| SCHEMBL6214667 | 0.82 | CHRNB2 (0.55) | CHRNB2CHRNA4P2RY14SIGMAR1SLC6A4 | |
| SCHEMBL6993886 | 0.82 | CHRNB2 (0.55) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL18111494 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14CCNT1CDK9 | |
| SCHEMBL16158125 | 0.80 | CHRNB2 (0.57) | CHRNB2CHRNA4CCNT1CDK9SLC6A4 | |
| SCHEMBL12093058 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4 | |
| SCHEMBL1023489 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068204-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND USE OF 8-AZABICYCLO 3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND UNLABELLED FORM | NEUROSEARCH A/S (DK) | 2001-01-17 | — | — | EP | claimed |
| WO-1999038866-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED FORM AND USE OF 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND UNLABELLED FORM | NEUROSEARCH A/S (DK) | 1999-08-05 | — | — | WO | claimed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| EP-1068204-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND USE OF 8-AZABICYCLO 3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND UNLABELLED FORM | NEUROSEARCH A/S (DK) | 2001-01-17 | — | — | EP | disclosed |
| US-6090808-A | PSYCHOLOGICAL DISORDERS; ANTICONVULSANTS | H. LUNDBECK A/S (DK) | 2000-07-18 | — | — | US | disclosed |
| WO-1999038866-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED FORM AND USE OF 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES IN LABELLED AND UNLABELLED FORM | NEUROSEARCH A/S (DK) | 1999-08-05 | — | — | WO | disclosed |
| EP-0649407-B1 | DIMERIC PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 1998-08-05 | — | — | EP | disclosed |
| US-5658921-A | POTENT SIGMA RECEPTOR LIGANDS; WATER SOLUBILITY; SYMMETRY | H. LUNDBECK A/S (DK) | 1997-08-19 | — | — | US | disclosed |
| EP-0649407-A1 | DIMERIC PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES | H. LUNDBECK A/S (DK) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993025527-A1 | DIMERIC PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES | H. LUNDBECK A/S (DK) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | CHRNB2 980/4885CHRNA4 1094/4885P2RY14 2961/4885 |
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | CHRNB2 197/4885CHRNA4 104/4885P2RY14 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.